VoICE Immunization Evidence

The impact of the U.S. maternal Tdap vaccination program on preventing pertussis in infants <2 months of age: a case-control evaluation

Authored by: Skoff TH, Blain AE, Watt J et al.

Appears in:

Key Concept

Key Evidence: Infants less than 2 months old are too young to be vaccinated against pertussis yet are at highest risk of severe disease – – a 75% hospitalization rate and a 1% case fatality rate. A case-control study in six U.S. states found that vaccinating women during the third trimester of pregnancy with Tdap vaccine provided 81% protection against pertussis to infants <2 months and 91% protection against hospitalized cases of pertussis.

Published In

Skoff TH, Blain AE, Watt J et al. 2017. The impact of the U.S. maternal Tdap vaccination program on preventing pertussis in infants <2 months of age: a case-control evaluation. Clinical Infectious Diseases. 65.

Disease or Vaccine